北京康辰药业股份有限公司 募集资金存放与使用情况鉴证报告 华兴专字[2025]25001570030 号 华兴会计师事务所（特殊普通合伙） w 募集资金存放与使用情况鉴证报告 华兴专字[2025]25001570030 号 北京康辰药业股份有限公司全体股东： 我们接受委托，对后附的北京康辰药业股份有限公司（以下简称康辰药 业）董事会编制的《关于2024年度募集资金存放与实际使用情况的专项报告》 （以下简称募集资金专项报告）执行了鉴证工作。 一、董事会的责任 康辰药业董事会的责任是提供真实、合法、完整的相关资料，按照中国 证券监督管理委员会《上市公司监管指引第2号——上市公司募集资金管理和 使用的监管要求》、上海证券交易所《上海证券交易所上市公司自律监管指引 第1号——规范运作》及《上海证券交易所上市公司自律监管指南第1号—— 公告格式》的规定编制募集资金专项报告。这种责任包括设计、执行和维护 与募集资金专项报告编制相关的内部控制，保证募集资金专项报告的真实、 准确和完整，以及不存在虚假记载、误导性陈述或重大遗漏。 二、注册会计师的责任 我们的责任是在实施鉴证工作的基础上对康辰药业董事会编制的募集资 金专项报告 ...

Financial Performance - The company's operating revenue for 2024 was CNY 825,397,797.20, a decrease of 10.28% compared to CNY 920,011,779.75 in 2023[24]. - Net profit attributable to shareholders for 2024 was CNY 42,216,726.62, down 71.94% from CNY 150,450,744.29 in 2023[24]. - Basic earnings per share for 2024 decreased to CNY 0.27, a decline of 71.88% from CNY 0.96 in 2023[25]. - The weighted average return on equity for 2024 was 1.36%, a decrease of 3.67 percentage points from 5.03% in 2023[25]. - The net cash flow from operating activities for 2024 was CNY 172,245,178.49, down 13.60% from CNY 199,353,548.33 in 2023[24]. - Total assets at the end of 2024 were CNY 3,919,688,890.45, an increase of 3.67% from CNY 3,780,818,095.19 at the end of 2023[24]. - The net assets attributable to shareholders at the end of 2024 were CNY 3,144,412,325.67, up 2.76% from CNY 3,059,941,948.61 at the end of 2023[24]. - The company reported a significant decline in net profit due to goodwill impairment related to the "Mige Xi" asset group[26]. - Non-recurring gains and losses for 2024 totaled CNY 11,139,947.75, compared to CNY 23,515,310.47 in 2023[30]. - The company received government subsidies amounting to CNY 3,972,168.12 in 2024, down from CNY 11,168,150.37 in 2023[29]. Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 6.00 per 10 shares, totaling approximately RMB 95.53 million, which represents 226.28% of the net profit attributable to shareholders for the year[8]. - The board of directors has approved the profit distribution plan for the fiscal year 2024, pending shareholder approval[8]. Audit and Compliance - The company has received a standard unqualified audit report from Huaxing Certified Public Accountants[7]. - The company has confirmed that all board members can guarantee the authenticity, accuracy, and completeness of the annual report[10]. - The company has no violations regarding decision-making procedures for external guarantees[9]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[9]. - The company has not disclosed any significant changes in its registered address or office location[19]. Research and Development - The company invested 139 million yuan in R&D, accounting for 16.83% of its revenue, with capitalized R&D expenses of 83.95 million yuan and expensed R&D costs of 54.94 million yuan[42]. - The company completed the Pre-NDA submission for ZY5301, which has reached its primary research endpoint in Phase III clinical trials[42]. - The company has established a talent pool and implemented a strict annual growth plan to enhance organizational vitality and competitiveness[37]. - The company has over 10 projects in the pre-research screening stage, primarily in the fields of perioperative, bone metabolism, tumors, and metabolic diseases, with multiple projects expected to enter clinical research by 2025[43]. - The company has a specialized R&D team of 89 members, accounting for 17.59% of the total workforce, with 96.7% holding at least a bachelor's degree[94]. Market and Product Development - In 2024, the company aims to transition from a "dual product support phase" to a "multiple products parallel phase," focusing on enhancing the potential value of its two main products, "Su Ling" and "Mi Gai Xi"[37]. - The company reported a revenue of 825 million yuan, a year-on-year decrease of 10.28%, primarily due to local procurement policies affecting "Mi Gai Xi" sales[38]. - "Su Ling" achieved a revenue of 592 million yuan, a year-on-year decrease of 3.54%, but the marketing transformation led to a 12.81% reduction in sales expenses[40]. - "Mi Gai Xi" generated a revenue of 233 million yuan, down 21.55% year-on-year, due to local procurement policies[41]. - The company is expanding into the pet medical market with a canine injection of Agkistrodon acutus venom, with registration application accepted in 2023 and supplementary research expected to be completed by Q1 2025[80]. Governance and Management - The annual report and summary for 2023 were approved during the shareholder meeting, along with the annual financial settlement report[182]. - The company plans to repurchase and cancel certain restricted stocks that have not yet been released from restrictions[182]. - The board of directors and supervisory board reports for 2023 were also approved during the meeting[182]. - The company is set to revise its "Independent Director Work System" and "Management Measures for Related Transactions" as part of its governance improvements[182]. - The company has established a salary assessment standard that considers external industry salary levels and the company's operational performance[190]. Strategic Initiatives and Future Outlook - The company aims to enter the top tier of China's pharmaceutical innovation enterprises by 2032, emphasizing high-quality development and a dual support strategy[157]. - The company plans to enhance its digital operations in 2025, aiming for improved data integration and operational efficiency[158]. - The company is committed to expanding its product pipeline through both internal innovation and external acquisitions, ensuring a diverse range of offerings[159]. - The company recognizes the risks associated with innovation and core competitiveness, which will be addressed through strategic initiatives[164]. - The company anticipates that the opportunities in 2025 will outweigh challenges, focusing on clinical research and digital promotion to improve drug accessibility[164].

Financial Performance - The company's operating revenue for Q1 2025 was CNY 212,002,399.05, representing a year-on-year increase of 6.41% compared to CNY 199,236,548.72 in the same period last year[4]. - Net profit attributable to shareholders was CNY 44,497,393.80, reflecting a 6.83% increase from CNY 41,654,332.06 in the previous year[4]. - The basic earnings per share (EPS) for the period was CNY 0.28, up 3.70% from CNY 0.27 in the same period last year[4]. - Total operating revenue for Q1 2025 reached ¥212,002,399.05, an increase of 6.9% compared to ¥199,236,548.72 in Q1 2024[21]. - Net profit for Q1 2025 was ¥48,137,550.37, compared to ¥46,845,096.86 in Q1 2024, representing an increase of 2.8%[21]. - The company's gross profit margin improved to approximately 77.5% in Q1 2025 from 76.8% in Q1 2024[21]. - Basic earnings per share for Q1 2025 were ¥0.28, compared to ¥0.27 in Q1 2024, indicating a slight increase[22]. Cash Flow and Liquidity - The net cash flow from operating activities was negative CNY 31,512,207.33, a significant decrease of 169.98% compared to a positive cash flow of CNY 45,031,453.62 in the previous year[4][7]. - In Q1 2025, the net cash flow from operating activities was -$31.51 million, a significant decline from $45.03 million in Q1 2024, representing a year-over-year decrease of 170%[26]. - Cash inflow from operating activities totaled $175.70 million in Q1 2025, down 21.4% from $223.45 million in Q1 2024[26]. - The company reported cash outflows from operating activities of $207.22 million in Q1 2025, an increase of 16.2% compared to $178.42 million in Q1 2024[26]. - The ending balance of cash and cash equivalents was $212.13 million in Q1 2025, down from $311.22 million in Q1 2024, a decrease of 31.9%[27]. - The company’s cash and cash equivalents increased by $22.15 million in Q1 2025, compared to an increase of $83.99 million in Q1 2024, indicating a decline of 73.6%[27]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 3,885,168,355.02, a decrease of 0.88% from CNY 3,919,688,890.45 at the end of the previous year[5]. - Total liabilities decreased to ¥445,504,171.41 from ¥493,524,893.69, a decline of 9.8%[18]. - The equity attributable to shareholders was CNY 3,154,272,355.95, showing a slight increase of 0.31% from CNY 3,144,412,325.67 at the end of the previous year[5]. - The company's equity attributable to shareholders increased to ¥3,154,272,355.95 from ¥3,144,412,325.67, a growth of 0.3%[18]. Research and Development - The company has completed the Phase III clinical trial for the innovative traditional Chinese medicine ZY5301, which targets chronic pelvic pain, and has submitted the new drug application for regulatory review[12]. - The KC1036 project has enrolled over 300 participants in clinical studies, demonstrating significant anti-tumor activity and good safety profiles, supporting its use in treating adolescent solid tumors[13]. - The KC1086 project has received clinical trial approval, aimed at treating advanced recurrent or metastatic solid tumors, marking a significant milestone for the company's R&D efforts[14]. - The company is actively communicating with regulatory authorities regarding the ZY5301 drug registration application, indicating a proactive approach to market entry[12]. Shareholder Information - The company had a total of 11,180 common shareholders at the end of the reporting period[9]. - The largest shareholder, Liu Jianhua, held 31.87% of the shares, amounting to 50,786,760 shares, with 8,846,840 shares pledged[9]. - The company has not reported any changes in the shareholding structure of the top 10 shareholders due to securities lending activities[11]. Other Financial Metrics - Non-recurring gains and losses for the period totaled CNY 597,771.28 after accounting for tax effects and minority interests[7]. - Research and development expenses decreased to ¥8,078,499.71 in Q1 2025 from ¥11,319,522.81 in Q1 2024, a reduction of 28.5%[21]. - Other comprehensive income for Q1 2025 showed a significant loss of ¥38,283,346.86, contrasting with a gain of ¥38,109,331.65 in Q1 2024[22]. - Cash flow from investing activities generated a net inflow of $38.64 million in Q1 2025, compared to $14.50 million in Q1 2024, marking a year-over-year increase of 166.5%[27].

北京康辰药业股份有限公司 2024 年度独立董事述职报告（李洪仪） 本人作为北京康辰药业股份有限公司（以下简称"公司"）第四届董事会的 独立董事，在任职期间严格按照《公司法》《证券法》《上市公司独立董事管理办 法》和《公司章程》等有关规定，独立客观、勤勉尽责地履职，及时了解公司的 生产经营和运行状况，积极参加公司召开的相关会议，认真审议董事会各项议案， 并结合自身的专业优势，充分发挥独立董事及各专门委员会委员的作用，切实维 护了公司、全体股东尤其是中小股东的合法权益。 现将 2024 年度履职情况报告如下： 一、独立董事的基本情况 本人李洪仪，男，1973 年 9 月出生，中国国籍，无境外永久居留权，中国 注册会计师协会资深会员。自 2003 年开始从事注册会计师业务，专注于审计、 咨询服务领域，专业经验丰富，曾任黑龙江省多宝山铜矿财务主管、北京普洋会 计师事务所项目经理、利安达会计师事务所有限责任公司部门经理、广西河池化 工股份有限公司独立董事，2011 年 1 月至今任大华会计师事务所（特殊普通合 伙）合伙人。2022 年 5 月至 2025 年 1 月任公司独立董事。 作为公司独立董事，本人任职期间，未 ...

北京康辰药业股份有限公司 舆情管理制度 第一章 总则 第一条 目的 为切实加强北京康辰药业股份有限公司（以下简称"公司"）应对各类舆 情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司品牌 形象、公司商业信誉、股价及正常生产经营活动造成的影响，切实保护投资者和 公司的合法权益，根据《上海证券交易所股票上市规则》等法律法规、规范性文 件的规定和《北京康辰药业股份有限公司章程》（以下简称"《公司章程》"） 的相关规定，结合公司实际情况，特制定本制度。 第二条 适用范围 本制度适用于公司及合并报表范围内的各级子公司。 第三条 舆情定义 第四条 舆情分类 （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活 动，使公司已经或可能遭受较大损失，已经或可能造成公司股票及其衍生品交易 价格异常波动的负面舆情。 本制度所称舆情包括： （一）报刊、电视、网络等媒体对公司进行的负面报道、不实报道。 （二）社会上存在的已经或将给公司造成不良影响的传言或信息。 （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息。 （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影 ...

北京康辰药业股份有限公司 2024 年度独立董事述职报告（翟永功） 2024 年度，本人作为北京康辰药业股份有限公司（以下简称"公司"）第四 届董事会的独立董事，严格按照《公司法》《证券法》《上市公司独立董事管理办 法》和《公司章程》等有关规定，独立客观、勤勉尽责地履职，及时了解公司的 生产经营和运行状况，积极参加公司召开的相关会议，认真审议董事会各项议案， 并结合自身的专业优势，充分发挥独立董事及各专门委员会委员的作用，切实维 护了公司、全体股东尤其是中小股东的合法权益。 现将公司 2024 年度履职情况报告如下： 一、独立董事的基本情况 本人翟永功，男，1961 年 10 月出生，中国国籍，无境外永久居留权，博士 学历。1984 年毕业于西北农林科技大学，获动物科学专业学士学位；1992 年毕 业于西北农林科技大学，获动物遗传育种专业的农学硕士学位；1999 年毕业于 西安交通大学，获生物医学工程博士学位；2005 年 1 月至 2007 年 1 月在美国匹 兹堡大学遗传药理学中心高级访问学者；先后公开发表学术论文 100 余篇、SCI 收录论文 40 余篇、参与编著教材和编著 5 部，并获得中国发明专利 ...

康辰药业（603590）公告，2024年营业收入8.25亿元，同比下降10.28%。归属于上市公司股东的净利润 4221.67万元，同比下降71.94%。公司于2025年4月25日召开第四届董事会第十六次会议，审议通过了 《关于2024年度利润分配预案的议案》，同意公司向2024年度利润分配实施公告确定的股权登记日可参 与分配的股东，每10股派发现金股利人民币6元(含税)。 ...

康辰药业（603590）公告，2025年第一季度营收为2.12亿元，同比增长6.41%；净利润为4449.74万元， 同比增长6.83%。 ...

证券代码：603590 证券简称：康辰药业 公告编号：临 2025-011 北京康辰药业股份有限公司 关于 KC1086 项目获得临床试验受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京康辰药业股份有限公司（以下简称"公司"）收到国家药品监督 管理局（以下简称"国家药监局"）核准签发的化学药品 1 类创新药 KC1086 片 的临床试验受理通知书，现将有关情况公告如下： 一、药品基本信息 药品名称：KC1086 片 规格： 1 mg、4 mg KC1086 展现出优异的体内外药效：在 ER+/HER2-的乳腺癌药效模型中，同 等剂量水平下 KC1086 对肿瘤生长具有更强的抑制作用，在其他实体瘤药效模型 中显示出类似的效果。KC1086 的 ADME 特性和安全性评价结果显示可有效解 决此类化合物的蓄积问题，且无明显的种属差异。 受理号：CXHL2500403、CXHL2500404 注册分类：化学药品 1 类 申请事项：境内生产药品注册临床试验 申请人：北京康辰药业股份有限公司 适应症：拟用于晚期 ...